Edit concept Question Editor Create issue ticket

Anti-HIV Agent

Aids Drugs


Presentation

  • BACKGROUND OF THE INVENTION The present invention relates to plant-derived high molecular weight substances which have potent anti-HIV activity.[google.com]
  • Data resulting from the use of the assay method for determination of dihydrocostatolide pharmacokinetics in mice are presented. This is the first report of a validated HPLC assay for determining DC levels in human and mouse plasma.[ncbi.nlm.nih.gov]
  • Late-breaking Poster Presentation. Tuesday, July 23, 12:30-14:30 CDT. Abstract LBPED46. J-M Molina et al.[biospace.com]
Weakness
  • Weak synergy was seen in combinations of TBR-652 with LPV, ATV, DRV, and ETV, mostly at sub-IC50 concentrations for both drugs in a pair. Additive effect was seen with TBR-652 plus TDF or RAL.[natap.org]
  • The vaccine would then deliver a weak, harmless type of virus that would introduce a section of DNA to a patient’s healthy muscle cells, containing instructions for how to produce this HIV-blocking protein.[notablelife.com]
  • The 2D IR spectrum at 4 C and pH* 8.9 shows an additional weak diagonal peak at 1,638 cm 1 (feature 2 in Fig. 3 H ). Moreover, ω 1 frequency slice ( SI Appendix , Fig.[pnas.org]
  • However, the effect of most of these agents are generally weak and they have severe side effects. In order to explore new type of anti-HIV substance, the present inventors have compared the anti-HIV activity of various plant components.[google.com]
Collapse
  • Fayer, Stanford University, Stanford, CA, and approved February 3, 2015 (received for review August 19, 2014) Significance The anti-HIV drug KP1212 was designed to intentionally increase the mutation rate of HIV, thereby causing viral population collapse[pnas.org]
  • If the replication error rate exceeds the “error catastrophe limit,” no viable progeny can be sustained and the viral population collapses ( 1 ).[pnas.org]
Gaucher Disease
  • DB00419 Miglustat For the treatment of adult patients with mild to moderate type 1 (nonneuropathic) Gaucher's disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to constraints such as allergy, hypersensitivity, or poor venous[drugbank.ca]
Pertussis
  • […] regulated upon activation, normal T cell expressed and secreted)- and stromal cell-derived factor (SDF)-1 alpha-stimulated chemotaxis (EC50 approximately equal to 1 nM) in leukocytes (THP-1, Jurkat, and peripheral blood lymphocyte cells) and activation of pertussis[ncbi.nlm.nih.gov]
Rhinitis
  • […] neuropathy NRTI Co-administration with TMP-SMZ increases bioavailability NRTI Contraindicated in patients with allergies to sulfanomides PI Adverse reaction: skin rash; drug interactions: inhibits cyp3A4 and cyp2C9 NNRTI Adverse reactions: GI discomfort, rhinitis[sporcle.com]
Photosensitivity
  • […] protease inhibitors Nelfinavir GI symptoms, rash Potent CYP3A4 inhibitor Induces its own metabolism Ritonavir GI symptoms, paresthesias , fatigue , lipid abnormalities, increased hepatic enzymes Induce its own metabolism Saquinavir Frequent side effects Photosensitivity[lecturio.com]
Uremia
  • […] antifungals, as well as protease inhibitors, increase plasma levels of zidovudine Rifampin increases zidovudine clearance Contraindications With caution in obese patients and patients with liver dysfunction Dose adjustment is required in patients with uremia[lecturio.com]
Peripheral Neuropathy
  • Used to prolong half life of other PIs PI Description agent class Adverse reaction: peripheral neuropathy NRTI Co-administration with TMP-SMZ increases bioavailability NRTI Contraindicated in patients with allergies to sulfanomides PI Adverse reaction[sporcle.com]
  • Dosages may be decreased by 50% if peripheral neuropathy occurs. May be taken without regard to meals. Must decrease dose in renal dysfunction. Stavudine and Zidovudine should not be co-administered.[globalrph.com]
  • Well tolerated because it does not affect the mitochondrial DNA synthesis or bone marrow precursor cells Stavudine Thymidine analog; penetrates the blood–brain barrier Peripheral neuropathy, headache, diarrhea, lipoatrophy, etc.[lecturio.com]
  • neuropathy. 02:55 Not listed here is also the fact that you can get headaches and fatigue from this medication. 03:00 Skin rash can also occur. 03:02 Although it's much less likely than other agents. 03:04 Now the other protease inhibitors are probably[lecturio.com]
  • Other side effects of anti-HIV drugs include pancreatitis, myopathy, anemia, peripheral neuropathy, nausea, and diarrhea. 33 Reducing Drug Toxicity The use of combination therapy: – Combining agents with favorable synergistic properties allows a decrease[slideplayer.com]
Neglect
  • The Rutgers WPF team members and ORWs specifically are anti HIV/AIDS agents, who work with an illiterate and neglected section of society.[comminit.com]

Workup

Nephrolithiasis
  • Given once daily PI Adverse reaction: nephrolithiasis, patient must be adequately hydrated PI NucleoTIDE analogue NRTI Given to pregnant women PI Inhibits and induces cyp3A4; adverse reactions: CNS toxicity, Gi intolerance, skin rash NNRTI Your Account[sporcle.com]
  • Nephrolithiasis : increased fluid intake is advised to prevent this Resistance: Develops due to selective point mutations in the pol gene.[lecturio.com]
  • Another major limiting toxicity is the high incidence of crystallization within kidney tubules and nephrolithiasis with one of the most potent PIs, indinavir ( 9 ) in addition to unconjugated hyperbilirubinemia and nephrolithiasis with atazanavir use.[cjasn.asnjournals.org]
Prolonged PR Interval
  • Summarized Important Points for other Commonly Used Protease Inhibitors Drug Adverse Effects Other Remarks Atazanavir GI symptoms, rash, hyperbilirubinemia , prolongs PR interval Food increases absorption and bioavailability Lower risk of hyperlipidemia[lecturio.com]

Treatment

  • DB04886 Calanolide A For use in combination treatment of HIV infection (AIDS). DB04961 Troxacitabine Investigated for use/treatment in leukemia (myeloid). DB05941 Leronlimab Investigated for use/treatment in HIV infection.[drugbank.ca]
  • […] was found to be a very potent anti-HIV-1 (EC50 6.76 microg mL(-1)) agent without cytotoxicity up to 100 microg mL(-1), indicating that the anti-HIV-1 activity found is similar to that of ddI (EC50 4.95 microg mL(-1)), which is used clinically for the treatment[ncbi.nlm.nih.gov]
  • When to start treatment Until recently, doctors weren’t sure of the best time to start HIV treatment. In 2015 a large, well-conducted study demonstrated that there are advantages to starting treatment as...[aidsmap.com]
  • […] of vector-borne diseases characterised by the agent Y02A50/381 — Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a virus Y02A50/384 — Medical treatment of vector-borne diseases characterised[google.ch]
  • […] or chemotherapy treatment within the next 48 weeks (with the exception of local treatment for Kaposi's sarcoma).[clinicaltrials.gov]

Prognosis

  • Abstract The establishment of anti-retroviral therapy has markedly improved the prognosis of patients with human immunodeficiency virus (HIV) infection.[jstage.jst.go.jp]

Etiology

  • Year introduced: 1997 PubMed search builder options Subheadings: administration and dosage adverse effects agonists analysis antagonists and inhibitors blood cerebrospinal fluid chemical synthesis chemistry classification economics etiology history immunology[ncbi.nlm.nih.gov]

Prevention

  • Although cosalane inhibits HIV-1 reverse transcriptase and protease, time of addition experiments indicate that it prevents the cytopathic effect of HIV by acting earlier than reverse transcription in the viral replication cycle.[ncbi.nlm.nih.gov]
  • Ever since the discovery of the virus as the causative agent, there has been an intense effort to develop therapeutic methods to inhibit or prevent infection.[thieme-connect.com]
  • An organization working on HIV/AIDS, Rutgers WPF, is one of the popular organizations working on harm reduction practice and HIV/AIDS prevention.[comminit.com]
  • The potential vaccine essentially copies the CCR5 co-receptor's proteins by binding to two sites on the surface of the virus simultaneously, and preventing HIV from entering the host cell.[natureworldnews.com]
  • Researchers at Yale University have discovered new chemical compounds that prevent HIV from replicating in human T-cells.[news.yale.edu]

Ask Question

5000 Characters left Format the text using: # Heading, **bold**, _italic_. HTML code is not allowed.
By publishing this question you agree to the TOS and Privacy policy.
• Use a precise title for your question.
• Ask a specific question and provide age, sex, symptoms, type and duration of treatment.
• Respect your own and other people's privacy, never post full names or contact information.
• Inappropriate questions will be deleted.
• In urgent cases contact a physician, visit a hospital or call an emergency service!